<DOC>
	<DOCNO>NCT01517620</DOCNO>
	<brief_summary>This prospective , randomize , open-label clinical trial evaluate efficacy safety total glucoside paeony capsule maintain clinical remission patient ankylose spondylitis achieve clinical remission anti-TNF therapy . Patients divide two group randomly , one group receive non-steroid anti-inflammatory drug ( NSAID ) mono-therapy group receive total glucoside paeony capsule plus NSAID therapy 24 week . The primary clinical endpoint proportion patient disease activity reach relapse criterion . The investigator 's hypothesis proportion relapse total glucoside paeony capsule plus NSAID group would lower NSAID mono-therapy group .</brief_summary>
	<brief_title>Total Glucosides Paeony Capsules Maintaining Clinical Remission Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Aged 1665 year , sign Informed Consent Fulfill 1984 modify NewYork classification criterion AS Achieved clinical remission least 12 week ' therapy antiTNF therapy Hb≥9g/dl , ALT/AST≤ 2 fold upper level normal range , creatine≤120mol/L ( ≤1.4mg/dl ) Commitment contraceptive woman History psoriasis and/or inflammatory bowel disease Receive intraarticular injection cortisone within 3 month enrollment History list disease : heart failure , Multiple sclerosis , severe chronic obstructive pulmonary disease , frequent infection , lymphoma cancer , tuberculosis Pregnant lactate woman Mentally ill , Alcoholics drug addict</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>